24 results on '"Xie, Jing‐Dun"'
Search Results
2. Systolic Blood Pressure and Cardiovascular Risk in Normotensive Adults
- Author
-
Cheng, Yun-Jiu, Luo, Dong-Ling, Bi, Wen-Tao, Mei, Wei-Yi, Wu, Su-Hua, Li, Zhu-Yu, and Xie, Jing-Dun
- Published
- 2023
- Full Text
- View/download PDF
3. Ac4C Enhances the Translation Efficiency of Vegfa mRNA and Mediates Central Sensitization in Spinal Dorsal Horn in Neuropathic Pain.
- Author
-
Xu, Ting, Wang, Jing, Wu, Yan, Wu, Jia‐Yan, Lu, Wei‐Cheng, Liu, Meng, Zhang, Su‐Bo, Xie, Dan, Xin, Wen‐Jun, and Xie, Jing‐Dun
- Subjects
NEURALGIA ,RNA modification & restriction ,MESSENGER RNA ,GENE expression ,NERVOUS system injuries ,TRANSVERSUS abdominis muscle - Abstract
N4‐Acetylcytidine (ac4C), a highly conserved post‐transcriptional machinery with extensive existence for RNA modification, plays versatile roles in various cellular processes and functions. However, the molecular mechanism by which ac4C modification mediates neuropathic pain remains elusive. Here, it is found that the enhanced ac4C modification promotes the recruitment of polysome in Vegfa mRNA and strengthens the translation efficiency following SNI. Nerve injury increases the expression of NAT10 and the interaction between NAT10 and Vegfa mRNA in the dorsal horn neurons, and the gain and loss of NAT10 function further confirm that NAT10 is involved in the ac4C modification in Vegfa mRNA and pain behavior. Moreover, the ac4C‐mediated VEGFA upregulation contributes to the central sensitivity and neuropathic pain induced by SNI or AAV‐hSyn‐NAT10. Finally, SNI promotes the binding of HNRNPK in Vegfa mRNA and subsequently recruits the NAT10. The enhanced interaction between HNRNPK and NAT10 contributes to the ac4C modification of Vegfa mRNA and neuropathic pain. These findings suggest that the enhanced interaction between HNRNPK and Vegfa mRNA upregulates the ac4C level by recruiting NAT10 and contributes to the central sensitivity and neuropathic pain following SNI. Blocking this cascade may be a novel therapeutic approach in patients with neuropathic pain. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Nalbuphine attenuates morphine‐induced scratching by inhibiting PKCβ‐dependent microglial activation and p38 phosphorylation in male mice.
- Author
-
Tang, Yang, Li, Nan‐Qi, Ye, Liu‐Qing, Yang, Fan, Huang, Si‐Ting, Peng, Zhe, Xie, Jing‐Dun, and Wan, Li
- Published
- 2023
- Full Text
- View/download PDF
5. Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord
- Author
-
Xie, Jing-Dun, Chen, Shao-Rui, Chen, Hong, and Pan, Hui-Lin
- Published
- 2017
- Full Text
- View/download PDF
6. Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo
- Author
-
Liu, Ke-Jun, He, Jie-Hua, Su, Xiao-Dong, Sim, Hong-May, Xie, Jing-Dun, Chen, Xing-Gui, Wang, Fang, Liang, Yong-Ju, Singh, Satyakam, Sodani, Kamlesh, Talele, Tanaji T., Ambudkar, Suresh V., Chen, Zhe-Sheng, Wu, Hai-Ying, and Fu, Li-Wu
- Published
- 2013
- Full Text
- View/download PDF
7. Prognostic value of SATB2 expression in patients with esophageal squamous cell carcinoma
- Author
-
Geng, Guo-Jun, Li, Ning, Mi, Yan-Jun, Yu, Xiu-Yi, Luo, Xian-Yang, Gao, Jing, Luo, Qi-Cong, Xie, Jing-Dun, Fa, Xian-En, and Jiang, Jie
- Subjects
Male ,Esophageal Neoplasms ,Kaplan-Meier Estimate ,Matrix Attachment Region Binding Proteins ,Middle Aged ,Prognosis ,digestive system diseases ,Disease-Free Survival ,Gene Expression Regulation, Neoplastic ,Survival Rate ,Biomarkers, Tumor ,Carcinoma, Squamous Cell ,Disease Progression ,Humans ,Original Article ,Female ,Transcription Factors - Abstract
SATB2, a member of the family of special AT-rich binding proteins, has been shown to affect numerous tumorigenesis. However, the role of SATB2 in esophageal squamous cell carcinoma (ESCC) remains unclear. In this study, the SATB2 expression was examined at mRNA and protein levels by quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR), Western blotting, and immunohistochemistry in ESCC tissues and adjacent non-cancerous tissues. Statistical analyses were applied to test the associations between SATB2 expression, clinicopathologic factors, and prognosis. Western blotting and qRT-PCR showed that the expression levels of SATB2 mRNA and protein were both significantly lower in SATB2 tissues than those in non-cancerous tissues. Immunohistochemistry analysis showed that SATB2 expression was significantly correlated with clinical stage and Histological differentiation. The results of Kaplan-Meier analysis indicated that a low expression level of SATB2 resulted in a significantly poor prognosis of ESCC patients. Importantly, multivariate analysis showed that low SATB2 expression was an independent prognostic factor for ESCC patients. In sum, our data suggest that SATB2 plays an important role in ESCC progression, and that decreased expression of SATB2 in tumor tissues could be used as a potential prognostic marker for patients with ESCC.
- Published
- 2015
8. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
- Author
-
Zhuang, Wei, Xie, Jing‐Dun, Zhou, Shan, Zhou, Zhi‐Wei, Zhou, Yi, Sun, Xiao‐Wei, Yuan, Xiu‐Hong, Huang, Min, Liu, Si, Xin, Shuang, Su, Qi‐Biao, Qiu, Hai‐Bo, and Wang, Xue‐Ding
- Subjects
- *
IMATINIB , *GASTROINTESTINAL stromal tumors , *TREATMENT of chronic myeloid leukemia , *DRUG side effects , *THERAPEUTICS , *TUMOR treatment - Abstract
Abstract: Imatinib at 400 mg daily is the standard treatment for patients affected with CML and GIST. The intervariability in plasma concentration is very significant. In many reports, a good therapeutic effect is attributed to an adequate concentration of Imatinib. However, few studies have been conducted to investigate the association between plasma concentration and side effects. Besides, no upper concentration limit of Imatinib plasma concentration detection has been established. The correlation of Imatinib trough concentrations (Cmin) with adverse effects (AEs) was described here. Plasma samples were obtained from patients after 3 months treatment with Imatinib (steady state,
n = 122). Liquid chromatography/ tandem mass spectrometry was used to determine the concentration of Imatinib and its metabolite NDI. The incidence of myelosuppression was increased significantly with the increased Imatinib trough plasma concentration. The plasma level of Imatinib and NDI in patients who developed myelosuppression are 1698.3 ± 598.6 ng/mL and 242.1 ng/mL, respectively, which were significantly higher than those in patients who did not (1327.2 ± 623.4 ng/mL,P =P =- Published
- 2018
- Full Text
- View/download PDF
9. Chloride Homeostasis Critically Regulates Synaptic NMDA Receptor Activity in Neuropathic Pain.
- Author
-
Li, Lingyong, Chen, Shao-Rui, Chen, Hong, Wen, Lei, Hittelman, Walter N., Xie, Jing-Dun, and Pan, Hui-Lin
- Abstract
Summary Chronic neuropathic pain is a debilitating condition that remains difficult to treat. Diminished synaptic inhibition by GABA and glycine and increased NMDA receptor (NMDAR) activity in the spinal dorsal horn are key mechanisms underlying neuropathic pain. However, the reciprocal relationship between synaptic inhibition and excitation in neuropathic pain is unclear. Here, we show that intrathecal delivery of K + -Cl − cotransporter-2 (KCC2) using lentiviral vectors produces a complete and long-lasting reversal of pain hypersensitivity induced by nerve injury. KCC2 gene transfer restores Cl − homeostasis disrupted by nerve injury in both spinal dorsal horn and primary sensory neurons. Remarkably, restoring Cl − homeostasis normalizes both presynaptic and postsynaptic NMDAR activity increased by nerve injury in the spinal dorsal horn. Our findings indicate that nerve injury recruits NMDAR-mediated signaling pathways through the disruption of Cl − homeostasis in spinal dorsal horn and primary sensory neurons. Lentiviral vector-mediated KCC2 expression is a promising gene therapy for the treatment of neuropathic pain. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice.
- Author
-
Xie, Jing-Dun, Huang, Yang, Chen, Dong-Tai, Pan, Jia-Hao, Bi, Bing-Tian, Feng, Kun-Yao, Huang, Wan, and Zeng, Wei-An
- Subjects
- *
FENTANYL , *HEPATOTOXICOLOGY , *PACLITAXEL , *LABORATORY mice , *ASPARTATE aminotransferase - Abstract
Fentanyl, a potent opioid analgesic that is used to treat cancer pain, is commonly administered with paclitaxel in advanced tumors. However, the effect of fentanyl on the hepatotoxicity of paclitaxel and its potential mechanism of action is not well studied. The purpose of this study was to investigate the effect of fentanyl on the hepatotoxicity of paclitaxel and its potential mechanisms of action. Pharmacokinetic parameters of paclitaxel were tested using reversed phase high-performance liquid chromatography (RP-HPLC). Aspartate transaminase (AST), alanine aminotransferase (ALT), and mouse liver histopathology were examined. Moreover, the cytotoxicity of anti-carcinogens was examined using 1-(4, 5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT), and the intracellular accumulation of doxorubicin and rhodamine 123 was detected by flow cytometry. Furthermore, the expression of ABCB1 and the activity of ABCB1 ATPase and CYP3A4 were also examined. In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice. Fentanyl significantly increased the levels of ALT in mice to 88.2 U/L, which is more than 2-fold higher than the level detected in the control group, and it increased the histological damage in mouse livers. Furthermore, fentanyl enhanced the cytotoxicity of anti-carcinogens that are ABCB1 substrates and increased the accumulation of doxorubicin and rhodamine 123. Additionally, fentanyl stimulated ABCB1 ATPase activity and inhibited CYP3A4 activity in the liver microsomes of mice. Our study indicates that the obvious hepatotoxicity during this co-administration was due to the inhibition of CYP3A4 activity and ABCB1 transport activity. These findings suggested that the accumulation-induced hepatotoxicity of paclitaxel when it is combined with fentanyl should be avoided. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. The α2δ-1-NMDA Receptor Complex Is Critically Involved in Neuropathic Pain Development and Gabapentin Therapeutic Actions.
- Author
-
Chen, Jinjun, Li, Lingyong, Chen, Shao-Rui, Chen, Hong, Xie, Jing-Dun, Sirrieh, Rita E., MacLean, David M., Zhang, Yuhao, Zhou, Meng-Hua, Jayaraman, Vasanthi, and Pan, Hui-Lin
- Published
- 2022
- Full Text
- View/download PDF
12. The prognostic effect of perineural invasion in esophageal squamous cell carcinoma.
- Author
-
Chen, Jie-Wei, Xie, Jing-Dun, Ling, Yi-Hong, Li, Peng, Yan, Shu-Mei, Xi, Shao-Yan, Luo, Rong-Zhen, Yun, Jing-Ping, Xie, Dan, and Cai, Mu-Yan
- Abstract
Background: Perineural invasion (PNI) is correlated with adverse survival in several malignancies, but its significance in esophageal squamous cell carcinoma (ESCC) remains to be clearly defined. The objective of this study was to determine the association between PNI status and clinical outcomes.Methods: We retrospectively evaluated the PNI of 433 patients with ESCC treated with surgery between 2000 and 2007 at a single academic center. The resulting data were analyzed using Spearman's rank correlation, the Kaplan-Meier method, Cox proportional hazards regression modeling and Harrell's concordance index (C-index).Results: PNI was identified in 209 of the 433 (47.7%) cases of ESCC. The correlation analysis demonstrated that PNI in ESCC was significantly correlated with tumor differentiation, infiltration depth, pN classification and stage (P < 0.05). The five-year overall survival rate was 0.570 for PNI-negative tumors versus 0.326 for PNI-positive tumors. Patients with PNI-negative tumors exhibited a 1.7-fold increase in five-year recurrence-free survival compared with patients with PNI-positive tumors (0.531 v 0.305, respectively; P < 0.0001). In the subset of patients with node-negative disease, PNI was evaluated as a prognostic predictor as well (P < 0.05). In the multivariate analysis, PNI was an independent prognostic factor for overall survival (P = 0.027). The C-index estimate for the combined model (PNI, gender and pN status) was a significant improvement on the C-index estimate of the clinicopathologic model alone (0.739 v 0.706, respectively).Conclusions: PNI can function as an independent prognostic factor of outcomes in ESCC patients, and the PNI status in primary ESCC specimens should be considered for therapy stratification. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
13. Distinct Thalamo-Subcortical Circuits Underlie Painful Behavior and Depression-Like Behavior Following Nerve Injury.
- Author
-
Deng J, Chen L, Liu CC, Liu M, Guo GQ, Wei JY, Zhang JB, Fan HT, Zheng ZK, Yan P, Zhang XZ, Zhou F, Huang SX, Zhang JF, Xu T, Xie JD, and Xin WJ
- Abstract
Clinically, chronic pain and depression often coexist in multiple diseases and reciprocally reinforce each other, which greatly escalates the difficulty of treatment. The neural circuit mechanism underlying the chronic pain/depression comorbidity remains unclear. The present study reports that two distinct subregions in the paraventricular thalamus (PVT) play different roles in this pathological process. In the first subregion PVT posterior (PVP), glutamatergic neurons (PVP
Glu ) send signals to GABAergic neurons (VLPAGGABA ) in the ventrolateral periaqueductal gray (VLPAG), which mediates painful behavior in comorbidity. Meanwhile, in another subregion PVT anterior (PVA), glutamatergic neurons (PVAGlu ) send signals to the nucleus accumbens D1-positive neurons and D2-positive neurons (NAcD1→D2 ), which is involved in depression-like behavior in comorbidity. This study demonstrates that the distinct thalamo-subcortical circuits PVPGlu →VLPAGGABA and PVAGlu →NAcD1→D2 mediated painful behavior and depression-like behavior following spared nerve injury (SNI), respectively, which provides the circuit-based potential targets for preventing and treating comorbidity., (© 2024 The Author(s). Advanced Science published by Wiley‐VCH GmbH.)- Published
- 2024
- Full Text
- View/download PDF
14. Functional dissection of parabrachial substrates in processing nociceptive information.
- Author
-
Ke J, Lu WC, Jing HY, Qian S, Moon SW, Cui GF, Qian WX, Che XJ, Zhang Q, Lai SS, Zhang L, Zhu YJ, Xie JD, and Huang TW
- Subjects
- Animals, Mice, Neurons physiology, Pain physiopathology, Male, Behavior, Animal physiology, Parabrachial Nucleus physiology, Nociception physiology
- Abstract
Painful stimuli elicit first-line reflexive defensive reactions and, in many cases, also evoke second-line recuperative behaviors, the latter of which reflects the sensing of tissue damage and the alleviation of suffering. The lateral parabrachial nucleus (lPBN), composed of external- (elPBN), dorsal- (dlPBN), and central/superior-subnuclei (jointly referred to as slPBN), receives sensory inputs from spinal projection neurons and plays important roles in processing affective information from external threats and body integrity disruption. However, the organizational rules of lPBN neurons that provoke diverse behaviors in response to different painful stimuli from cutaneous and deep tissues remain unclear. In this study, we used region-specific neuronal depletion or silencing approaches combined with a battery of behavioral assays to show that slPBN neurons expressing substance P receptor ( NK1R ) (lPBN
NK1R ) are crucial for driving pain-associated self-care behaviors evoked by sustained noxious thermal and mechanical stimuli applied to skin or bone/muscle, while elPBN neurons are dispensable for driving such reactions. Notably, lPBNNK1R neurons are specifically required for forming sustained somatic pain-induced negative teaching signals and aversive memory but are not necessary for fear-learning or escape behaviors elicited by external threats. Lastly, both lPBNNK1R and elPBN neurons contribute to chemical irritant-induced nocifensive reactions. Our results reveal the functional organization of parabrachial substrates that drive distinct behavioral outcomes in response to sustained pain versus external danger under physiological conditions.- Published
- 2024
- Full Text
- View/download PDF
15. Antinociceptive effectiveness of the inhibition of NCX reverse-mode action in rodent neuropathic pain model.
- Author
-
Huang Y, Wen LL, Xie JD, Ouyang HD, Chen DT, and Zeng WA
- Subjects
- Analgesics administration & dosage, Animals, Calcium metabolism, Disease Models, Animal, Injections, Spinal, Isoflurane administration & dosage, Isoflurane therapeutic use, Male, Mitogen-Activated Protein Kinases metabolism, Rats, Sprague-Dawley, Sodium-Calcium Exchanger metabolism, Analgesics therapeutic use, Neuralgia drug therapy
- Published
- 2019
- Full Text
- View/download PDF
16. The α2δ-1-NMDA Receptor Complex Is Critically Involved in Neuropathic Pain Development and Gabapentin Therapeutic Actions.
- Author
-
Chen J, Li L, Chen SR, Chen H, Xie JD, Sirrieh RE, MacLean DM, Zhang Y, Zhou MH, Jayaraman V, and Pan HL
- Subjects
- Animals, Calcium Channels deficiency, Calcium Channels metabolism, Calcium Channels, L-Type chemistry, Gabapentin pharmacology, HEK293 Cells, Humans, Male, Mice, Knockout, Posterior Horn Cells metabolism, Posterior Horn Cells pathology, Protein Binding, Rats, Synapses metabolism, Calcium Channels, L-Type metabolism, Gabapentin therapeutic use, Neuralgia drug therapy, Neuralgia metabolism, Receptors, N-Methyl-D-Aspartate metabolism
- Abstract
α2δ-1, commonly known as a voltage-activated Ca
2+ channel subunit, is a binding site of gabapentinoids used to treat neuropathic pain and epilepsy. However, it is unclear how α2δ-1 contributes to neuropathic pain and gabapentinoid actions. Here, we show that Cacna2d1 overexpression potentiates presynaptic and postsynaptic NMDAR activity of spinal dorsal horn neurons to cause pain hypersensitivity. Conversely, Cacna2d1 knockdown or ablation normalizes synaptic NMDAR activity increased by nerve injury. α2δ-1 forms a heteromeric complex with NMDARs in rodent and human spinal cords. The α2δ-1-NMDAR interaction predominantly occurs through the C terminus of α2δ-1 and promotes surface trafficking and synaptic targeting of NMDARs. Gabapentin or an α2δ-1 C terminus-interfering peptide normalizes NMDAR synaptic targeting and activity increased by nerve injury. Thus, α2δ-1 is an NMDAR-interacting protein that increases NMDAR synaptic delivery in neuropathic pain. Gabapentinoids reduce neuropathic pain by inhibiting forward trafficking of α2δ-1-NMDAR complexes., (Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
17. Presynaptic mGluR5 receptor controls glutamatergic input through protein kinase C-NMDA receptors in paclitaxel-induced neuropathic pain.
- Author
-
Xie JD, Chen SR, and Pan HL
- Subjects
- Animals, Antineoplastic Agents, Phytogenic adverse effects, Behavior, Animal drug effects, Cells, Cultured, Evoked Potentials drug effects, Excitatory Amino Acid Agonists pharmacology, Excitatory Amino Acid Antagonists administration & dosage, Excitatory Amino Acid Antagonists pharmacology, Excitatory Amino Acid Antagonists therapeutic use, Glycine analogs & derivatives, Glycine pharmacology, Injections, Spinal, Male, Nerve Tissue Proteins agonists, Nerve Tissue Proteins antagonists & inhibitors, Neuralgia chemically induced, Neuralgia drug therapy, Neuralgia pathology, Neurons, Afferent drug effects, Neurons, Afferent pathology, Paclitaxel adverse effects, Protein Kinase C antagonists & inhibitors, Protein Kinase Inhibitors pharmacology, Pyridines administration & dosage, Pyridines pharmacology, Pyridines therapeutic use, Rats, Sprague-Dawley, Receptor, Metabotropic Glutamate 5 agonists, Receptor, Metabotropic Glutamate 5 antagonists & inhibitors, Receptors, N-Methyl-D-Aspartate antagonists & inhibitors, Resorcinols pharmacology, Spinal Cord Dorsal Horn drug effects, Spinal Cord Dorsal Horn pathology, Synaptosomes drug effects, Synaptosomes metabolism, Synaptosomes pathology, Nerve Tissue Proteins metabolism, Neuralgia metabolism, Neurons, Afferent metabolism, Protein Kinase C metabolism, Receptor, Metabotropic Glutamate 5 metabolism, Receptors, N-Methyl-D-Aspartate metabolism, Spinal Cord Dorsal Horn metabolism
- Abstract
Chemotherapeutic drugs such as paclitaxel cause painful peripheral neuropathy in many cancer patients and survivors. Although NMDA receptors (NMDARs) at primary afferent terminals are known to be critically involved in chemotherapy-induced chronic pain, the upstream signaling mechanism that leads to presynaptic NMDAR activation is unclear. Group I metabotropic glutamate receptors (mGluRs) play a role in synaptic plasticity and NMDAR regulation. Here we report that the Group I mGluR agonist ( S )-3,5-dihydroxyphenylglycine (DHPG) significantly increased the frequency of miniature excitatory postsynaptic currents (EPSCs) and the amplitude of monosynaptic EPSCs evoked from the dorsal root. DHPG also reduced the paired-pulse ratio of evoked EPSCs in spinal dorsal horn neurons. These effects were blocked by the selective mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP), but not by an mGluR1 antagonist. MPEP normalized the frequency of miniature EPSCs and the amplitude of evoked EPSCs in paclitaxel-treated rats but had no effect in vehicle-treated rats. Furthermore, mGluR5 protein levels in the dorsal root ganglion and spinal cord synaptosomes were significantly higher in paclitaxel- than in vehicle-treated rats. Inhibiting protein kinase C (PKC) or blocking NMDARs abolished DHPG-induced increases in the miniature EPSC frequency of spinal dorsal horn neurons in vehicle- and paclitaxel-treated rats. Moreover, intrathecal administration of MPEP reversed pain hypersensitivity caused by paclitaxel treatment. Our findings suggest that paclitaxel-induced painful neuropathy is associated with increased presynaptic mGluR5 activity at the spinal cord level, which serves as upstream signaling for PKC-mediated tonic activation of NMDARs. mGluR5 is therefore a promising target for reducing chemotherapy-induced neuropathic pain., (© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
18. The Prognostic Value of Peripheral Benzodiazepine Receptor in Patients with Esophageal Squamous Cell Carcinoma.
- Author
-
Chen YF, Xie JD, Jiang YC, Chen DT, Pan JH, Chen YH, Yuan YF, Wen ZS, and Zeng WA
- Abstract
Background: The peripheral benzodiazepine receptor (PBR) has previously been reported as an oncogene in prostate, breast and colorectal cancers, but its prognostic value, biological behavior and function in esophageal squamous cell carcinoma (ESCC) has not been investigated. Methods: qRT-PCR, western blotting and immunohistochemistry (IHC) were used to detect PBR expression in ESCC and matched non-cancerous tissues. Based on all of the significantly independent factors, a nomogram was established to predict the prognosis of ESCC patients. In addition, we performed comprehensive in vitro experiments to study the functions of PBR in cell growth, colony formation, and migration ability, as well as its relationship with epithelial-mesenchymal transition (EMT) related proteins in ESCC cells. Results: The mRNA and protein expression levels of PBR in ESCC were higher than those in adjacent non-tumor esophageal epithelial tissues. The IHC results demonstrated that PBR expression was an independent prognostic factor in ESCC survival, patients with higher PBR expression had a poorer survival than those with low expression, and PBR expression was significantly associated with lymphoid nodal status. Furthermore, a nomogram was established to reliably predict the probability of death in ESCC patients, with a Harrell's c-index of 0.696. In the vitro experiments, knocking down the expression of PBR inhibited proliferation, colony formation and migration of ESCC cells, and regulated EMT-associated proteins (up-regulation of E-cadherin, ZO-1 and β-catenin and concomitant with down-regulation of Fibronectin and N-cadherin). Conclusions: PBR is an independent prognostic factor in ESCC, and it promotes ESCC progression and metastasis. Basing on PBR expression level, a nomogram is established and performs a well in predicting survival of ESCC patients., Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
- Published
- 2017
- Full Text
- View/download PDF
19. Old age at diagnosis increases risk of tumor progression in nasopharyngeal cancer.
- Author
-
Xie JD, Chen F, He YX, Chen XD, Zhang GY, Li ZK, Hong J, Xie D, and Cai MY
- Subjects
- Age Factors, China epidemiology, Disease Progression, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Nasopharyngeal Neoplasms epidemiology, Nasopharyngeal Neoplasms mortality, Nasopharyngeal Neoplasms therapy, Prognosis, ROC Curve, Retrospective Studies, Survival Rate, Chemoradiotherapy mortality, Nasopharyngeal Neoplasms pathology
- Abstract
Age at diagnosis has been found to be a prognostic factor of outcomes in various cancers. However, the effect of age at diagnosis on nasopharyngeal cancer (NPC) progression has not been explored. We retrospectively evaluated the relationship between age and disease progression in 3,153 NPC patients who underwent radiotherapy, chemotherapy, or chemoradiotherapy between 2007 and 2009. Patients were randomly assigned to either a testing cohort or a validation cohort by computer-generated random assignment. X-tile plots determined the optimal cut-point of age based on survival status to be ≤61 vs. >61 years. Further correlation analysis showed that age >61 years was significantly correlated with the tumor progression and therapeutic regimen in both testing and validation cohorts (P <0.05). In the present study, we observed that older age (>61 years) was a strong and independent predictor of poor disease-free survival (DFS) and cancer-specific survival (CSS), in both univariate and multivariate analyses. Age was also found to be a significant prognostic predictor as well (P <0.05) when evaluating patients with the same disease stage. ROC analysis confirmed the predictive value of age on NPC-specific survival in both cohorts (P <0.001) and suggested that age may improve the ability to discriminate outcomes in NPCs, especially regarding tumor progression. In conclusion, our study suggests that older age at NPC diagnosis is associated with a higher incidence of tumor progression and cancer-specific mortality. Age is a strong and independent predictor of poor outcomes and may allow for more tailored therapeutic decision-making and individualized patient counseling.
- Published
- 2016
- Full Text
- View/download PDF
20. Presynaptic N-Methyl-d-aspartate (NMDA) Receptor Activity Is Increased Through Protein Kinase C in Paclitaxel-induced Neuropathic Pain.
- Author
-
Xie JD, Chen SR, Chen H, Zeng WA, and Pan HL
- Subjects
- 2-Amino-5-phosphonovalerate pharmacology, Animals, Ganglia, Spinal metabolism, Male, Neuralgia chemically induced, Neuralgia pathology, Paclitaxel pharmacology, Rats, Rats, Sprague-Dawley, Spinal Cord metabolism, Neuralgia metabolism, Paclitaxel adverse effects, Presynaptic Terminals metabolism, Protein Kinase C metabolism, Receptors, N-Methyl-D-Aspartate metabolism
- Abstract
Painful peripheral neuropathy is a severe adverse effect of chemotherapeutic drugs such as paclitaxel (Taxol). The glutamate N-methyl-d-aspartate receptors (NMDARs) are critically involved in the synaptic plasticity associated with neuropathic pain. However, paclitaxel treatment does not alter the postsynaptic NMDAR activity of spinal dorsal horn neurons. In this study, we determined whether paclitaxel affects presynaptic NMDAR activity by recording excitatory postsynaptic currents (EPSCs) of dorsal horn neurons in spinal cord slices. In paclitaxel-treated rats, the baseline frequency of miniature EPSCs (mEPSCs) was significantly increased; the NMDAR antagonist 2-amino-5-phosphonopentanoic acid (AP5) completely normalized this frequency. Also, AP5 significantly reduced the amplitude of monosynaptic EPSCs evoked by dorsal root stimulation and reversed the reduction in the paired-pulse ratio of evoked EPSCs in paclitaxel-treated rats. Blocking GluN2A-containing, but not GluN2B-containing, NMDARs largely decreased the frequency of mEPSCs and the amplitude of evoked EPSCs of dorsal horn neurons in paclitaxel-treated rats. Furthermore, inhibition of protein kinase C fully reversed the increased frequency of mEPSCs and the amplitude of evoked EPSCs in paclitaxel-treated rats. Paclitaxel treatment significantly increased the protein level of GluN2A and phosphorylated GluN1 in the dorsal root ganglion. In addition, intrathecal injection of AP5 or systemic administration of memantine profoundly attenuated pain hypersensitivity induced by paclitaxel. Our findings indicate that paclitaxel treatment induces tonic activation of presynaptic NMDARs in the spinal cord through protein kinase C to potentiate nociceptive input from primary afferent nerves. Targeting presynaptic NMDARs at the spinal cord level may be an effective strategy for treating chemotherapy-induced neuropathic pain., (© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
21. Prognostic value of SATB2 expression in patients with esophageal squamous cell carcinoma.
- Author
-
Geng GJ, Li N, Mi YJ, Yu XY, Luo XY, Gao J, Luo QC, Xie JD, Fa XE, and Jiang J
- Subjects
- Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Disease Progression, Disease-Free Survival, Esophageal Neoplasms mortality, Esophageal Neoplasms pathology, Female, Humans, Kaplan-Meier Estimate, Male, Matrix Attachment Region Binding Proteins genetics, Middle Aged, Prognosis, Survival Rate, Transcription Factors genetics, Biomarkers, Tumor, Carcinoma, Squamous Cell metabolism, Esophageal Neoplasms metabolism, Gene Expression Regulation, Neoplastic, Matrix Attachment Region Binding Proteins metabolism, Transcription Factors metabolism
- Abstract
SATB2, a member of the family of special AT-rich binding proteins, has been shown to affect numerous tumorigenesis. However, the role of SATB2 in esophageal squamous cell carcinoma (ESCC) remains unclear. In this study, the SATB2 expression was examined at mRNA and protein levels by quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR), Western blotting, and immunohistochemistry in ESCC tissues and adjacent non-cancerous tissues. Statistical analyses were applied to test the associations between SATB2 expression, clinicopathologic factors, and prognosis. Western blotting and qRT-PCR showed that the expression levels of SATB2 mRNA and protein were both significantly lower in SATB2 tissues than those in non-cancerous tissues. Immunohistochemistry analysis showed that SATB2 expression was significantly correlated with clinical stage and Histological differentiation. The results of Kaplan-Meier analysis indicated that a low expression level of SATB2 resulted in a significantly poor prognosis of ESCC patients. Importantly, multivariate analysis showed that low SATB2 expression was an independent prognostic factor for ESCC patients. In sum, our data suggest that SATB2 plays an important role in ESCC progression, and that decreased expression of SATB2 in tumor tissues could be used as a potential prognostic marker for patients with ESCC.
- Published
- 2015
22. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
- Author
-
Cheng C, Liu ZG, Zhang H, Xie JD, Chen XG, Zhao XQ, Wang F, Liang YJ, Chen LK, Singh S, Chen JJ, Talele TT, Chen ZS, Zhong FT, and Fu LW
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, ATP Binding Cassette Transporter, Subfamily G, Member 2, Animals, Cell Line, Cell Line, Tumor, Drug Interactions, HEK293 Cells, HL-60 Cells, Humans, MCF-7 Cells, Male, Mice, Mice, Inbred BALB C, Mice, Nude, Neoplastic Stem Cells drug effects, Neoplastic Stem Cells metabolism, ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism, ATP-Binding Cassette Transporters metabolism, Antineoplastic Agents pharmacology, Aurora Kinases antagonists & inhibitors, Drug Resistance, Multiple drug effects, Imidazoles pharmacology, Neoplasm Proteins metabolism, Protein Kinase Inhibitors pharmacology, Pyridines pharmacology
- Abstract
Imidazopyridine CCT129202 is an inhibitor of Aurora kinase activity and displays a favorable antineoplastic effect in preclinical studies. Here, we investigated the enhanced effect of CCT129202 on the cytotoxicity of chemotherapeutic drugs in multidrug resistant (MDR) cells with overexpression of ATP-binding cassette (ABC) transporters and cancer stem-like cells. CCT129202 of more than 90% cell survival concentration significantly enhanced the cytotoxicity of substrate drugs and increased the intracellular accumulations of doxorubicin and rhodamine 123 in ABCB1 and ABCG2 overexpressing cells, while no effect was found on parental sensitive cells. Interestingly, CCT129202 also potentiated the sensitivity of cancer stem-like cells to doxorubicin. Importantly, CCT129202 increased the inhibitory effect of vincristine and paclitaxel on ABCB1 overexpressing KBv200 cell xenografts in nude mice and human esophageal cancer tissue overexpressing ABCB1 ex vivo, respectively. Furthermore, the ATPase activity of ABCB1 was inhibited by CCT129202. Homology modeling predicted the binding conformation of CCT129202 within the large hydrophobic cavity of ABCB1. On the other hand, CCT129202 neither apparently altered the expression levels of ABCB1 and ABCG2 nor inhibited the activity of Aurora kinases in MDR cells under the concentration of reversal MDR. In conclusion, CCT129202 significantly reversed ABCB1- and ABCG2-mediated MDR in vitro, in vivo and ex vivo by inhibiting the function of their transporters and enhanced the eradication of cancer stem-like cells by chemotherapeutic agents. CCT129202 may be a candidate as MDR reversal agent for antineoplastic combination therapy and merits further clinical investigation.
- Published
- 2012
- Full Text
- View/download PDF
23. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.
- Author
-
Zhao XQ, Xie JD, Chen XG, Sim HM, Zhang X, Liang YJ, Singh S, Talele TT, Sun Y, Ambudkar SV, Chen ZS, and Fu LW
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, ATP-Binding Cassette Transporters metabolism, Adenosine Triphosphatases genetics, Adenosine Triphosphatases metabolism, Animals, Antineoplastic Agents pharmacology, Cell Line, Tumor, Doxorubicin pharmacology, Drug Resistance, Multiple drug effects, Drug Resistance, Multiple genetics, Drug Resistance, Neoplasm drug effects, Drug Resistance, Neoplasm genetics, HEK293 Cells, HL-60 Cells, Humans, Mice, Mice, Inbred BALB C, Mice, Nude, Oncogene Protein v-akt genetics, Oncogene Protein v-akt metabolism, Phosphorylation drug effects, RNA, Messenger genetics, Rhodamines pharmacology, rho-Associated Kinases genetics, rho-Associated Kinases metabolism, ATP Binding Cassette Transporter, Subfamily B, Member 1 genetics, ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism, ATP-Binding Cassette Transporters genetics, Quinolines pharmacology
- Abstract
Neratinib, an irreversible inhibitor of epidermal growth factor receptor and human epidermal receptor 2, is in phase III clinical trials for patients with human epidermal receptor 2-positive, locally advanced or metastatic breast cancer. The objective of this study was to explore the ability of neratinib to reverse tumor multidrug resistance attributable to overexpression of ATP-binding cassette (ABC) transporters. Our results showed that neratinib remarkably enhanced the sensitivity of ABCB1-overexpressing cells to ABCB1 substrates. It is noteworthy that neratinib augmented the effect of chemotherapeutic agents in inhibiting the growth of ABCB1-overexpressing primary leukemia blasts and KBv200 cell xenografts in nude mice. Furthermore, neratinib increased doxorubicin accumulation in ABCB1-overexpressing cell lines and Rhodamine 123 accumulation in ABCB1-overexpressing cell lines and primary leukemia blasts. Neratinib stimulated the ATPase activity of ABCB1 at low concentrations but inhibited it at high concentrations. Likewise, neratinib inhibited the photolabeling of ABCB1 with [(125)I]iodoarylazidoprazosin in a concentration-dependent manner (IC(50) = 0.24 μM). Neither the expression of ABCB1 at the mRNA and protein levels nor the phosphorylation of Akt was affected by neratinib at reversal concentrations. Docking simulation results were consistent with the binding conformation of neratinib within the large cavity of the transmembrane region of ABCB1, which provides computational support for the cross-reactivity of tyrosine kinase inhibitors with human ABCB1. In conclusion, neratinib can reverse ABCB1-mediated multidrug resistance in vitro, ex vivo, and in vivo by inhibiting its transport function.
- Published
- 2012
- Full Text
- View/download PDF
24. Effect of dicycloplatin, a novel platinum chemotherapeutical drug, on inhibiting cell growth and inducing cell apoptosis.
- Author
-
Li GQ, Chen XG, Wu XP, Xie JD, Liang YJ, Zhao XQ, Chen WQ, and Fu LW
- Subjects
- Antineoplastic Agents chemistry, Antineoplastic Agents toxicity, Caspase 3 metabolism, Caspase 8 metabolism, Cell Line, Tumor, Cell Proliferation drug effects, Drug Combinations, Gene Expression Regulation, Neoplastic, Hep G2 Cells, Humans, Membrane Potential, Mitochondrial drug effects, Models, Biological, Platinum chemistry, Platinum toxicity, Poly(ADP-ribose) Polymerases metabolism, Reactive Oxygen Species metabolism, Receptors, Death Domain metabolism, Signal Transduction drug effects, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Protein p53 metabolism, Antineoplastic Agents pharmacology, Apoptosis drug effects, Glutamates pharmacology, Organoplatinum Compounds pharmacology, Platinum pharmacology
- Abstract
Dicycloplatin, a new supramolecular platinum-based antitumor drug, has been approved by the State Food and Administration (SFDA) of China. In this study, we investigated the anticancer activity of dicycloplatin in cancer cells and signaling pathways involved in dicycloplatin-induced apoptosis. Dicycloplatin inhibited the proliferation of cancer cells and increased the percentage of apoptosis in a concentration-dependent manner. Besides, some apoptosis related events were observed after treatment with dicycloplatin, including increase of reactive oxygen species (ROS), collapse of mitochondrial membrane potential (Δψm), release of cytochrome c from the mitochondria to the cytosol, upregulation of p53, which were accompanied by activation of caspase-9, caspase-3, caspase-8, and poly (ADP-ribose) polymerase cleavage in a concentration-dependent manner. The role of apoptosis in dicycloplatin-mediated cell death was further confirmed by the concomitant treatment with caspase-8 or caspase-9 inhibitors, which inhibited apoptosis and PARP cleavage. Intracellular glutathione (GSH) was also found to inhibit the cytotoxic effect of dicycloplatin. In conclusion, these findings suggest that dicycloplatin induces apoptosis through ROS stress-mediated death receptor pathway and mitochondrial pathway which is similar to carboplatin.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.